News

An Affordable Care Act payment model is showing that chronically ill patients can be better taken care of in their own homes while bringing down the long-term cost of care.

The Managed Healthcare Executive Editorial Advisory Board says these skills are critical to be a successful healthcare executive today. Do you have what it takes?

During the keynote session at the Advanced Payment Models in Healthcare Conference 2016, PwC experts shared how MACRA legislation will affect reimbursement.

New Health Care Cost Institute analysis examines the value that can be derived from providing cost and quality information for non-emergency healthcare services.

FDA recently approved Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] for the treatment of hemophilia B. Here are the top 6 facts to know about Idelvion.

The Centers for Disease Control and Prevention (CDC) issued new voluntary guidelines this week for prescribing opioid medications for chronic pain, excluding cancer, palliative, and end-of-life care.

We asked industry insiders to detail and analyze each component of Trump’s healthcare plan.

Captives can serve as focal points for the captive owners’ collective efforts to promote safer healthcare environments and improved patient outcomes.

US hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study.

Surprising way a group of surveyed physicians are saying what they think is the best way to control costs.

Effective teams transform patient and caregiver experience by building trust and meeting goals. Here are five ways how.

FDA has approved expanded indication for the use of fulvestrant (Faslodex, AstraZeneca) in combination with another therapy in the treatment of metastatic breast cancer.

While FDA just approved the first generic version of sildenafil citrate (Viagra, Pfizer), the new product won’t be on the market until late 2017.

The 2016 Alternative Payment Models in Healthcare Conference 2016 is shedding light on which healthcare payment and delivery changes are evolving into large-scale, long-lasting solutions.

Learning to use mobile health or mhealth is a critical advantage to providing the highest return on investment for plans and providers.

The use of insulin management software in hospital emergency departments can decrease hospital admissions for diabetic ketoacidosis (DKA) by 45%, according to a new study.

While insurance companies and employers are deploying more pricing tools, healthcare providers are in a unique position to lead the price transparency revolution.

FDA has approved Odefsey (Gilead Sciences, Inc.) for the treatment of HIV-1 infection in certain patients. Here are the top 7 facts to know about Odefsey.

Health insurance plans will soon receive ratings based on how many doctors and hospitals they include in their networks.

While FDA recently approved ibrutinib (Imbruvica, Janssen Biotech, Inc. and Pharmacyclics LLC) to treat patients with chronic lymphocytic leukemia (CLL), United Kingdom’s National Institute of Health and Care Excellence (NICE) will not yet recommend the medication.

New data from Novo Nordisk will help its Victoza (liraglutide) for type 2 diabetes better compete against Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin). Victoza significantly reduced the combined incidence of heart attack, stroke and cardiovascular death in high-risk Type 2 diabetes patients, according to Novo Nordisk

Prior authorizations are here to stay. Are yours working against you? Find out.

While many Americans and legislators have complained about the rising cost of medications in recent years, seniors are likely impacted more than the population at large. The average retail price among 622 prescription medications widely used by seniors doubled from 2006 to 2013, to reach more than $11,000, according to the American Association of Retired Persons’ (AARP)’s updated “Rx Price Watch” report.

Model set to improve compliance, reduce costs, but reimbursement challenges remain.

Factors include rising costs of brand medications, increased specialty therapy use

Highlights include Medicaid specialty drug reimbursement, managing ICD-10 implementation

Shared resources, specialized drugs key to curbing costs